LEXINGTON, Mass.--(BUSINESS WIRE)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced new clinical data for ferumoxytol (Feraheme®), the company’s treatment for iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). These data were presented on Saturday, December 10, 2011, at a poster session at the American Society of Hematology annual meeting in San Diego, CA.
